BioNTech
- Country
- 🇩🇪Germany
- Ownership
- Public
- Employees
- 6.1K
- Market Cap
- $20.7B
- Website
- http://www.biontech.de
- Introduction
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in M...
A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children
- Conditions
- Interventions
- First Posted Date
- 2021-03-25
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 11837
- Registration Number
- NCT04816643
- Locations
- 🇺🇸
Madera Family Medical Group, Madera, California, United States
🇺🇸Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸SKY Integrative Medical Center/SKYCRNG, Ridgeland, Mississippi, United States
Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2021-03-24
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 1500
- Registration Number
- NCT04813627
- Locations
- 🇺🇸
Oncology Hematology Care Clinical Trials, LLC, Cincinnati, Ohio, United States
🇺🇸John Muir Clinical Research Center, Concord, California, United States
🇺🇸Ridley-Tree Cancer Center, California City, California, United States
To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older
- Conditions
- Interventions
- First Posted Date
- 2021-02-15
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 726
- Registration Number
- NCT04754594
- Locations
- 🇪🇸
Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸Hospital Sant Joan de Deu, Esplugues de Llobregat, Barcelona, Spain
🇪🇸Hospital Quironsalud Barcelona, Barcelona, Spain
A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2021-01-19
- Last Posted Date
- 2022-12-22
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 1574
- Registration Number
- NCT04713553
- Locations
- 🇺🇸
Clinical Research Consulting, Milford, Connecticut, United States
🇺🇸Clinical Research Atlanta, Stockbridge, Georgia, United States
🇺🇸Amici Clinical Research LLC, Raritan, New Jersey, United States
Dose Escalation Trial of BNT152+153 in Patients With Cancer
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 170
- Registration Number
- NCT04710043
- Locations
- 🇺🇸
Duke Cancer Center, Durham, North Carolina, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸NEXT Oncology, San Antonio, Texas, United States
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 13
- Registration Number
- NCT04683939
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸START, San Antonio, Texas, United States
🇨🇦University of Montreal - Centre Hospitalier de l´Université de Montréal, Montréal, Canada
Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2022-05-10
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 950
- Registration Number
- NCT04649021
- Locations
- 🇨🇳
Jiangsu Provincial Center for Disease Control and Prevention, Jiangsu, China
Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults
- Conditions
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 160
- Registration Number
- NCT04588480
- Locations
- 🇯🇵
SOUSEIKAI Sumida Hospital, Sumida-ku, Tokyo, Japan
🇯🇵SOUSEIKAI PS Clinic, Fukuoka, Japan
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
- First Posted Date
- 2020-09-03
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 96
- Registration Number
- NCT04537949
- Locations
- 🇩🇪
Contract Research Organization, Mannheim, Germany
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
- Conditions
- Interventions
- First Posted Date
- 2020-09-01
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 285
- Registration Number
- NCT04534205
- Locations
- 🇧🇷
Fundacao Universidade de Caxias do Sul - Instituto de Pesquisas em Saude IPS-UCS, Caxias Do Sul, Brazil
🇧🇷Hospital Erasto Gaertner, Curitiba, Brazil
🇧🇷Hospial de Caridade de Ijui, IjuÃ, Brazil